Kimberlee C.  Drapkin net worth and biography

Kimberlee Drapkin Biography and Net Worth

Kim Drapkin brings to Jounce more than 20 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Ms. Drapkin has worked with Jounce since its inception, playing a key role in building Jounce’s financial infrastructure, and comes into this role with an already deep understanding of Jounce’s strategy and culture. Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early-stage biotechnology companies, including Jounce, Eleven Biotherapeutics, Inc., NinePoint Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer Pharmaceuticals and Voyager Therapeutics, Inc. Previously, Ms. Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms. Drapkin spent ten years in roles of increasing responsibility within the finance organization at Millennium Pharmaceuticals. Ms. Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP.

Ms. Drapkin received her B.S. in accounting from Babson College.

What is Kimberlee C. Drapkin's net worth?

The estimated net worth of Kimberlee C. Drapkin is at least $138,742.12 as of January 9th, 2023. Ms. Drapkin owns 73,799 shares of Jounce Therapeutics stock worth more than $138,742 as of March 29th. This net worth estimate does not reflect any other investments that Ms. Drapkin may own. Learn More about Kimberlee C. Drapkin's net worth.

How do I contact Kimberlee C. Drapkin?

The corporate mailing address for Ms. Drapkin and other Jounce Therapeutics executives is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. Jounce Therapeutics can also be reached via phone at (857) 259-3840 and via email at [email protected]. Learn More on Kimberlee C. Drapkin's contact information.

Has Kimberlee C. Drapkin been buying or selling shares of Jounce Therapeutics?

Kimberlee C. Drapkin has not been actively trading shares of Jounce Therapeutics within the last three months. Most recently, Kimberlee C. Drapkin sold 6,315 shares of the business's stock in a transaction on Monday, January 9th. The shares were sold at an average price of $1.10, for a transaction totalling $6,946.50. Following the completion of the sale, the chief financial officer now directly owns 73,799 shares of the company's stock, valued at $81,178.90. Learn More on Kimberlee C. Drapkin's trading history.

Who are Jounce Therapeutics' active insiders?

Jounce Therapeutics' insider roster includes Kimberlee Drapkin (CFO), John Higgons (Director), Richard Murray (CEO), and Elizabeth Trehu (Insider). Learn More on Jounce Therapeutics' active insiders.

Are insiders buying or selling shares of Jounce Therapeutics?

During the last year, insiders at the sold shares 1 times. They sold a total of 39,228 shares worth more than $72,571.80. The most recent insider tranaction occured on April, 4th when Director Richard /Ca/ Murray sold 39,228 shares worth more than $72,571.80. Insiders at Jounce Therapeutics own 6.9% of the company. Learn More about insider trades at Jounce Therapeutics.

Information on this page was last updated on 4/4/2023.

Kimberlee C. Drapkin Insider Trading History at Jounce Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2023Sell6,315$1.10$6,946.5073,799View SEC Filing Icon  
1/10/2022Sell8,222$6.65$54,676.30View SEC Filing Icon  
1/7/2022Sell4,595$7.30$33,543.50View SEC Filing Icon  
1/21/2021Sell30,000$11.36$340,800.0058,897View SEC Filing Icon  
1/7/2021Sell2,697$6.76$18,231.7259,011View SEC Filing Icon  
9/1/2020Sell7,200$8.06$58,032.0061,708View SEC Filing Icon  
8/17/2020Sell454$4.86$2,206.4470,106View SEC Filing Icon  
8/14/2020Sell984$4.64$4,565.7670,106View SEC Filing Icon  
1/7/2020Sell2,624$7.78$20,414.7244,390View SEC Filing Icon  
8/15/2019Sell648$4.00$2,592.0048,680View SEC Filing Icon  
3/8/2018Sell5,267$25.01$131,727.675,267View SEC Filing Icon  
3/5/2018Sell5,267$21.42$112,819.142,775View SEC Filing Icon  
See Full Table

Kimberlee C. Drapkin Buying and Selling Activity at Jounce Therapeutics

This chart shows Kimberlee C Drapkin's buying and selling at Jounce Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Jounce Therapeutics Company Overview

Jounce Therapeutics logo
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $1.88
Low: $1.88
High: $1.93

50 Day Range

MA: $1.89
Low: $1.84
High: $1.94

2 Week Range

Now: $1.88
Low: $0.58
High: $5.87

Volume

11,600,600 shs

Average Volume

2,457,142 shs

Market Capitalization

$98.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75